Here's Why Bausch Health Stock Gained 14.7% in a Week
BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push ...
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...
Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name
This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...
With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels
Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...
Private Equity Interest Signals Upside for Bausch + Lomb: A Buy Rating Justified
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...
Bausch + Lomb, Calibre, Dexterra at 52-Week Highs
Bausch + Lomb Corporation (T.BLCO) hit a new 52-week high of $27.36 Wednesday. No news stories available today. Calibre ...
Buy Rating Reaffirmed for Bausch Health on Prospective Bausch + Lomb Sale and Value Unlocking
Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...
Bausch + Lomb soars on report that it’s exploring a sale
A sale could value Bausch + Lomb at more than $13 billion, according to Bloomberg Intelligence analyst Mike Holland. The news is “certainly welcome to investors tied up in the Gordian’s knot at Bausch ...
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
Bausch + Lomb Corp (NYSE:BLCO) is reportedly considering a sale as it navigates separation issues from its parent company, ...
medtechdive7d
Bausch + Lomb considers sale: FT
Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.